top of page


  • AutorenbildJuergen Mairhofer

New research study demonstrates enGenes-express glycosyltransferase yield advantages

New research study demonstrates enGenes-express glycosyltransferase yield advantages

News-ReleasesEnGenes Biotech GmbH

February 7th 2019

Vienna, Austria: – Recombinant protein specialist manufacturer enGenes Biotech GmbH (enGenes) has welcomed a new scientific publication showing successful application of its proprietary enGenes-eXpress technology in significantly improving recombinant protein yields of difficult-to-express plant glycosyltransferases.

It demonstrates five-fold increases in yields of glycosyltransferase when using the enGenes-eXpress strain compared to a state-of-the-art strain BL21(DE3), with a doubling in enzyme quality.

Peer-reviewed study

The study ‘Decoupling of recombinant protein production from Escherichia coli cell growth enhances functional expression of plant Leloir glycosyltransferases’ has been published in the prestigious journal Biotechnology and Bioengineering (DOI:10.1002/bit.26934).

The study has been leaded by Prof. Bernd Nidetzky, Head of the Institute of Biotechnology and Biochemical Engineering at Technical University Graz and CSO of ACIB GmbH, with contributions from enGenes CEO Dr. Juergen Mairhofer, and three other TU Graz and ACIB GmbH researchers, Martin Lemmerer, Alexander Lepak and Karin Longus and enGenes long-time collaborator Assoc. Prof. Dr. Rainer Hahn, affiliated to the University of Natural Resources and Life Sciences Vienna (BOKU).

The study is the result of collaborative research funded by the Austrian Research Promotion Agency, the FFG.


bottom of page